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Abstract
Objectives It is not certain from current evidence which patient groups with non-visible haematuria (NVH) require urgent 
investigation and which investigations are sufficient. We report referral outcomes data from Scotland to identify patient 
groups who will benefit from urgent assessment to rule out urological cancer (UC) and whether full set of investigations 
are necessary in all referred patients.
Materials and methods Data were collected from electronic patient records for patients referred with NVH to secondary care 
urology services between July 2017 and May 2020. The correlations between risk factors and final diagnosis were assessed 
using categorical variables in a multivariate logistic regression analysis and using chi-squared models. Statistical analysis 
was performed using IBM SPSS data editor version 25.
Results Our study cohort comprised 525 patients (43.4% males; median age 66 years), in which UC was diagnosed in 25 
patients (4.8%). Age > 60 years had sensitivity and NPV for UC of 92% and 99%, respectively. Univariate and multivariate 
analysis showed male sex, age ≥ 60 years and smoking were significant predictors of UC in patients with NVH (p < 0.05). 
There was no significant difference in UC in patients with history of LUTS, anticoagulation and previous UC.
Conclusion The risk of urologic cancer in NVH patients is significant and male gender, age ≥ 60 years and smoking are sig-
nificant predictors of UC. Patients with risk factors of UC require complete assessment of both the upper and lower urinary 
tract; however, in the absence of risk factors, patients do not require urgent or complete assessment.
Keywords Microscopic haematuria · Urological cancer · Risk factors
Introduction
The prevalence of non-visible haematuria (NVH) in the 
general population is around 2.5% but variability is seen 
with gender and age groups [1, 2]. Various methods and 
definitions were used to detect NVH but in practical terms, 
urine dipstick testing is a feasible and cost-effective method 
particularly in general practice [3, 4]. The studies have 
confirmed accuracy of dipstick haematuria with quanti-
tative red blood cell microscopy [3, 5]. NVH referrals to 
secondary care are based on dipstick testing which is the 
preferred method for assessment in general practice [4]. The 
main concern is to exclude urological cancer and a recent 
metanalysis reported that NVH evaluation detected, bladder 
cancer (BC), kidney cancer (KC) and upper tract urothelial 
cancer (UTUC) in 3.2%, 0.28% and 0.04% of cases, respec-
tively [6]. In general, diagnostic yield of significant benign 
cause is in the range of 28–38% and up to 100% including all 
less significant causes, depending on the method of investi-
gations and population [7–9].
Investigation of NVH includes checking renal functions, 
upper tract assessment with imaging and flexible cystoscopy, 
along with clinical examination. Appropriate assessment of 
NVH uses significant resources, carries a cost and is also a 
challenge on already stretched secondary care urology ser-
vices in NHS system [4, 10]. There is no uniform guidance 
on assessment of NVH patient [3]. NICE guideline for NVH 
suggests an urgent referral in patients aged ≥ 60 with dysu-
ria or a raised white cell count and non-urgent referral in 
aged ≥ 60 with no explainable cause for NVH [11].
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It is not certain from current evidence which patient 
groups with NVH require urgent investigation and which 
investigations are sufficient. We report referral outcomes 
data from Scotland to identify patient groups who will ben-
efit from urgent assessment to rule out urological cancer and 
whether full set of investigations are necessary in all patients 
referred with NVH.
Materials and methods
Data were collected from electronic patient records for 
patients presenting with non-visible haematuria between 
July 2017 and May 2020. A search was made for all patients 
referred with non-visible haematuria.
NVH was defined when urine dipstick was positive for 
3 + blood on 2 consecutive urine samples, 1–2 weeks apart 
in the absence of urinary tract infection (UTI). All patients 
with new onset NVH regardless of symptoms were included 
in the study. Patients with recurrent NVH, under 16 years 
and incomplete investigations were excluded.
Our NVH assessment protocol include clinical history 
(smoking, symptoms, previous urological history, co-mor-
bidities, medications and family history), focussed urologi-
cal examination including digital rectal examination (DRE) 
in males, renal functions, full blood count, ultrasound kid-
neys and bladder (USS KUB), urine dipstick (urine culture 
where appropriate) and flexible cystoscopy (FC). Per-vaginal 
examination was not routinely performed. USS KUB was 
omitted in patients who already had upper tract assessment 
(CT urogram, CT Kidneys and Bladder (CT KUB), MRI 
Kidneys, MR urogram or CT Abdomen & Pelvis) within 
3 months of referral for NVH. For patients with no malig-
nancy at initial investigation, all subsequent electronic refer-
ral or admission records (including urology and other spe-
cialties) and radiological investigations were reviewed for 
9 months, to assess any missed urological cancers.
Asymptomatic patients with urine dipstick positive for 
suspected UTI proceeded to FC under antibiotic cover or 
deferred till further evaluation for UTI at the discretion of 
the assessing urologist. In patients with UTI based on symp-
toms regardless of a positive urine dipstick for leucocytes 
and nitrites at the time of assessment, FC was deferred till 
UTI was treated with antibiotics and negative urine culture 
obtained. Once treated for UTI, these patients were relisted 
for completion FC. In those treated who required treatment 
for UTI prior to completion FC, we did not look for NVH 
as these initially had NVH in absence of UTI as per above 
NVH definition.
Lower urinary tract symptoms (LUTS) were defined as 
presence of storage or voiding symptoms. If further assess-
ment based on severity of symptoms was needed, these 
patients were further followed up in designated LUTS clinic 
where IPSS scores, QoL questions and flow studies were 
done. For statistical analysis, we only assessed presence or 
absence of LUTS based on the above definition.
If patient was continually smoking at the time of refer-
ral or stopped smoking ≤ 1 year, it is defined as smoker. 
However, if smoking cessation was ≥ 1 year, it was labelled 
as Ex-smoker. For statistical analysis smoking variable 
included smokers and Ex-smokers.
Patients were divided in groups based on diagnostic 
pathology, gender, age, symptoms, and smoking history. 
Statistical analysis was done using IBM SPSS data editor 
version 25. Fisher’s exact test and chi-squared tests were 
applied to analyse the relationships between categorical 
variables. Differences between continuous variables were 
assessed by ANOVA and Mann–Whitney U test (where 
appropriate). The correlations between risk factors and final 
diagnosis were assessed using categorical variables in a mul-
tivariate logistic regression analysis and using chi-squared 
models. Risk factors associated with all malignancy (pros-
tate, bladder, urethral, kidney) and bladder malignancy alone 
were interpreted.
Results
Our study cohort comprised 525 patients (43.4% males; 
median age 66 years) who were referred for the evaluation 
of NVH from primary care service. History of smoking was 
present in 247 (47%), LUTS in 227 (43.2%), anticoagulation 
in 142 (27%) and previous cancer in 42 (8%). USS was the 
commonest investigation in 371 (70.7%) while CT scan was 
performed in 109 (20.8%). Combination of USS and CT was 
required in 38 (7.2%) while 5 (1%) already had MRI abdo-
men due to non-urological reasons when referred for NVH. 
Benign prostate enlargement 67 (12.8%) was the most identi-
fied pathology where benign diagnosis was made (Table 1).
Urological cancer (UC) was diagnosed in 25 patients 
(4.8%). Bladder cancer was the commonest cancer in 20 
(3.8%) followed by renal and prostate cancer in 3 (0.6%) 
and 2 (0.4%), respectively. Median age was 77 years (IQR 
15) in GU cancer patients while in patients with no cause 
or benign pathology median age was 65 years (IQR 22), 
p < 0.0001. ROC analysis of age (years) cutoff values to 
detect UC showed a cut of value of 60 years provided the 
highest combined sensitivity and specificity of 92% and 
40.2%, respectively.
UC was diagnosed in 18 patients (7.3%) of 247 patients 
(47%) with history of smoking and no difference was dem-
onstrated for UC between ex-smokers and current smok-
ers (9.2% and 4.8%, p = 0.22), respectively. There was 
no significant difference in UC in patients with history 
of LUTS, anticoagulation, antiplatelet therapy and previ-
ous UC. On univariate and multivariate analysis male sex, 
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age ≥ 60 years and smoking (current smoking or ex-smok-
ing) were significant predictors of UC in patients with NVH, 
p < 0.05 (Tables 2, 3). The combined factors of male sex, 
age > 60 years and smoking have a sensitivity, specificity, 
PPV and NPV for UC of 48.0%, 83.3%, 24.5% and 97.4%, 
respectively. The presence of at least one of the variables 
(male sex, age > 60 years, smoking) has a sensitivity, spec-
ificity, PPV and NPV of 100%, 16.7%, 5.3%, 100%. The 
presence of at least two of the variables has a sensitivity, 
specificity, PPV and NVP of 80%, 45.6%, 6.4%, 98.0%.
Benign urological pathology (BUP) and no urological 
cause (NUC) were found in 183 (35%) and 317 (60.4%). 
Median ages between BUP and NUC were 70 years (IQR 
18) and 60 (IQR 22; p < 0.0001). In 215 patients ≤ 60 years, 
NUC, BUP and UC (Bladder and renal) were found in 
73.5%, 25.6% and 0.9% (0.45% and 0.45%), respectively. In 
49 patients ≤ 40 years of age, NUC, BUP and UC were found 
in 75.5%, 24.5% and 0%, respectively.
Discussion
Although a cause for NVH be found in over 32%, significant 
causes are found in a much lower proportion of cases [7, 9]. 
The combined percentage of patients with either urological 
cancer or significant non-cancer causes, ranges from 0 to 
16% [6, 12, 13]. Edwards et al. evaluated 4020 haematuria 
patients and found urological malignancy in 4.8% of patients 
in the NVH group, while Mishriki et al. reported 6% urologi-
cal cancer yield on assessment of 292 asymptomatic NVH 
patients [13, 14]. Our study also reports a low rate of uro-
logical cancer (4.8%) in this patient cohort. Some studies, 
such as Khan et al. report an even lower rate of UC in NVH 
patients (1.6%) [15]. A possible explanation is that we con-
sidered 3 + urine dipstick as threshold for NVH assessment. 
Jung et al. report increasing incidence of urologic malig-
nancy with increasing degree of NVH [16].
Sensitivity and specificity of USS versus CT for detec-
tion for renal tumours were 14.3% and 100% versus 89% 
and 99.6%, respectively [6, 17]. UTUC detection in patients 
with NVH is 0.042% in NVH patients. In view of low inci-
dence and categorising patients with risk factors for further 
assessment with CTU, chances of missing an UTUC is very 
unlikely with initial assessment with USS. It picks up indi-
rect signs and based on these, further CTU assessment can 
be planned to exclude significant upper tract pathology. For 
upper tract assessment in NVH, USS kidney is the investi-
gation of choice at our institution. Ongoing review of the 
subsequent referrals and radiological imaging for 9 months 
of our cohort makes it unlikely that we missed UTUC.
Despite full assessment of non-visible haematuria with 
cystoscopy, upper tract imaging and renal functions, often 
no pathology is identified. Mishriki et al. reports that 44% 
Table 1  Patient characteristics and summary of findings




 Current smoker 105 20
 Ex-smoker 142 27
 Non smoker 278 53
Renal function
 eGFR ≥ 60 485 92.4
 Not done 5 1
Co morbidities
 Hypertension 133 25.3
 Ischaemic heart disease/atrial fibrillation 89 17
 Diabetes mellitus 35 6.7
 Chronic obstructive pulmonary disease 44 8.4
 Chronic kidney disease (any stage) 39 7.4
 Miscellaneous 156 29.7
 Any comorbidity 415 79
Urological causes
No urological cause found 317 60.4
Urological cancer 25 4.8
Benign prostatic enlargement 67 12.8
UTI 41 7.8
Urolithiasis (renal/ureter/bladder) 23 4.4
Bladder neck stenosis/urethral stricture 20 3.8
Miscellaneous 32 6.1
Total 525 100.0
Table 2  Univariate logistic regression analysis of clinical predictors 
for urological cancer in NVH patients
Odds ratio p value CI (95%)
Male sex 4.41 0.002 1.73 11.23
Age ≥ 60 (years) 7.73 0.006 1.8 33.15
Smoker or ex-smoker 3.04 0.014 1.25 7.41
LUTS 0.87 0.74 0.38 2
Antiplatelet and/or 
anticoagulation
1.8 0.14 0.81 4.24
Table 3  Multivariate logistic regression analysis of clinical predictors 
for urological cancer in NVH patients
Odds ratio p value CI (95%)
Male 3.13 0.019 1.21 8.14
Age ≥ 60 (years) 6.00 0.017 1.37 26.23
Smoker or ex-smoker 2.54 0.045 1.02 6.32
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of patients have no pathology. Our findings suggest that up 
to 60.4% of patients have no underlying pathology.
Our findings suggest that a significant number of patients 
have benign pathology (34.9%), the majority of which is not 
significant. We believe that the high percentage of benign 
prostate hypertrophy most likely did not contribute to the 
non-visible haematuria, albeit there were some cases of 
hyper vascular prostates. In view of the low likelihood of 
cancer, yet high chance of non-significant/no pathology, 
there is a need to identify risk groups where full urgent 
assessment will be more appropriate versus those where 
a limited assessment should be sufficient. This will utilise 
resources more efficiently and save cost.
Studies have shown patients < 50 years with NVH to 
have a very low incidence of urological malignancy [12–14, 
18]. The present study found no urological cancers in the 
patients ≤ 40 years and 75.5% had normal assessment. There 
were 2 patients with urological cancer < 60 years, one had 
upper tract cancer and another had carcinoma in situ. This 
showed extremely low incidence of urological cancer (0.9%) 
in this age group and 73.4% had normal investigations. Other 
studies such as Murakami et al. report a significant differ-
ence between sex; 6.6% and 1.6% urological cancer detection 
in males and females, respectively. Although bladder cancer 
was found in 1.25%, the vast majority were males; while in 
females, renal cancer was common [12]. Our study detected 
urological cancer in 8.3% and 2% of males and females, 
respectively, consistent with the findings of Murakami et al.
A study from Denmark conducted by Elmussareh et al. 
suggested asymptomatic NVH should not be routinely evalu-
ated due to the low incidence of UC in patients with NVH. 
From January 2016 they revised their guidelines and NVH 
is no longer routinely investigated. Retrospective analyses 
of asymptomatic NVH referrals in Denmark report that this 
revised guideline would result in 0.8% (11/1305) to 1.5% 
(10/687) missed benign and malignant urological tumours 
[10, 11]. Instead of disregarding the evaluation of NVH 
completely, we encourage clinicians to use patient factors 
to guide both the decision to investigate and the urgency of 
investigation.
In our institution, all NVH patients referred to the urol-
ogy department are investigated with renal function, DRE 
(males), Ultrasound kidneys and bladder (USS KUB) and a 
flexible cystoscopy. There is a need to lessen the strain on 
secondary urology services by prioritising patients at high 
risk of harbouring urological malignancy and significant 
benign urological causes. The risk factors as identified in the 
present study can be used as the basis of patient prioritisa-
tion to prevent overwhelming utilisation of urology services. 
In the absence of risk factors, patients can safely be investi-
gated non-urgently (> 2 weeks) or indeed undergo a limited 
assessment, depending on the availability of resources.
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